174 related articles for article (PubMed ID: 29698433)
1. Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment.
Rashidi FB; AlQhatani AD; Bashraheel SS; Shaabani S; Groves MR; Dömling A; Goda SK
PLoS One; 2018; 13(4):e0196254. PubMed ID: 29698433
[TBL] [Abstract][Full Text] [Related]
2. Production of "biobetter" glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment.
AlQahtani AD; Al-Mansoori L; Bashraheel SS; Rashidi FB; Al-Yafei A; Elsinga P; Domling A; Goda SK
Eur J Pharm Sci; 2019 Jan; 127():79-91. PubMed ID: 30343151
[TBL] [Abstract][Full Text] [Related]
3. Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy.
Moradbeygi F; Ghasemi Y; Farmani AR; Hemmati S
Biomed Pharmacother; 2023 Oct; 166():115292. PubMed ID: 37579696
[TBL] [Abstract][Full Text] [Related]
4. Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.
Al-Qahtani AD; Bashraheel SS; Rashidi FB; O'Connor CD; Romero AR; Domling A; Goda SK
Biomed Pharmacother; 2019 Apr; 112():108725. PubMed ID: 30970523
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a Stable Form of Carboxypeptidase G2 (Glucarpidase), a Potential Biobetter Variant, From Acinetobacter sp. 263903-1.
Sadeghian I; Hemmati S
Mol Biotechnol; 2021 Dec; 63(12):1155-1168. PubMed ID: 34268672
[TBL] [Abstract][Full Text] [Related]
6. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
Aldughaim MS; Alsaffar F; Barker MD
Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy.
Rowsell S; Pauptit RA; Tucker AD; Melton RG; Blow DM; Brick P
Structure; 1997 Mar; 5(3):337-47. PubMed ID: 9083113
[TBL] [Abstract][Full Text] [Related]
8. Functional overexpression and purification of a codon optimized synthetic glucarpidase (carboxypeptidase G2) in Escherichia coli.
Goda SK; Rashidi FA; Fakharo AA; Al-Obaidli A
Protein J; 2009 Dec; 28(9-10):435-42. PubMed ID: 19911261
[TBL] [Abstract][Full Text] [Related]
9. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
[TBL] [Abstract][Full Text] [Related]
10. Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.
Al-Mansoori L; Al Qahtani AD; Elsinga P; Goda SK
Technol Cancer Res Treat; 2021; 20():15330338211057371. PubMed ID: 34802309
[No Abstract] [Full Text] [Related]
11. Soluble expression, purification and functional characterisation of carboxypeptidase G2 and its individual domains.
Jeyaharan D; Aston P; Garcia-Perez A; Schouten J; Davis P; Dixon AM
Protein Expr Purif; 2016 Nov; 127():44-52. PubMed ID: 27374188
[TBL] [Abstract][Full Text] [Related]
12. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics.
Spencer DI; Robson L; Purdy D; Whitelegg NR; Michael NP; Bhatia J; Sharma SK; Rees AR; Minton NP; Begent RH; Chester KA
Proteomics; 2002 Mar; 2(3):271-9. PubMed ID: 11921443
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
[TBL] [Abstract][Full Text] [Related]
14. Nanosecond electric pulses deprive zinc ions of carboxypeptidase G2.
Yu T; Fu X
Bioelectrochemistry; 2015 Feb; 101():42-5. PubMed ID: 25049063
[TBL] [Abstract][Full Text] [Related]
15. Engineering carboxypeptidase G2 circular permutations for the design of an autoinhibited enzyme.
Yachnin BJ; Khare SD
Protein Eng Des Sel; 2017 Apr; 30(4):321-331. PubMed ID: 28160000
[TBL] [Abstract][Full Text] [Related]
16. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
Springer CJ; Poon GK; Sharma SK; Bagshawe KD
Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of the Carboxypeptidase G2 Catalytic Site and Design of New Inhibitors for Cancer Therapy.
Jeyaharan D; Brackstone C; Schouten J; Davis P; Dixon AM
Chembiochem; 2018 Sep; 19(18):1959-1968. PubMed ID: 29968955
[TBL] [Abstract][Full Text] [Related]
18. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).
Francis RJ; Mather SJ; Chester K; Sharma SK; Bhatia J; Pedley RB; Waibel R; Green AJ; Begent RH
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1090-6. PubMed ID: 15029458
[TBL] [Abstract][Full Text] [Related]
19. Diethylstilbestrol glutamate as a potential substrate for ADEPT.
Pedone E; Searle F; Brocchini S
J Drug Target; 2006 Jul; 14(6):437-43. PubMed ID: 17092843
[TBL] [Abstract][Full Text] [Related]
20. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial.
Sharma SK; Bagshawe KD; Melton RG; Sherwood RF
Cell Biophys; 1992; 21(1-3):109-20. PubMed ID: 1285323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
